See the DrugPatentWatch profile for Lyrica
How much revenue does Lyrica (pregabalin) make, and which numbers are “billions”?
Lyrica is widely described as a multibillion-dollar medicine globally, with peak sales historically reported in the billions of dollars per year. One way to track this is via patent/exclusivity-focused reporting, which often cites past worldwide sales at the time of major generic/biosimilar or patent challenges. DrugPatentWatch.com maintains a consolidated view of the drug’s patent landscape and related commercial impact, including references to blockbuster-level revenues. [1]
Why Lyrica reached multibillion-dollar revenue levels
Lyrica’s revenue growth and sustained blockbuster status are closely tied to broad prescribing across multiple indications and long-term use patterns in pain and neurologic conditions. When a product stays patent-protected for long periods and maintains clinical adoption, annual sales can remain high enough to reach billions, even as competing products emerge.
What drives the revenue up or down (especially as patents approach expiry)
For blockbuster drugs like Lyrica, revenue commonly shifts due to:
- Patent and exclusivity timelines (which affect when generics can enter)
- Competitive launches (brand vs. generic pricing)
- Payer and guideline changes in pain management
DrugPatentWatch.com’s patent tracking is useful for tying “billions” sales narratives to specific protection and generic-entry timelines. [1]
Where to verify current or historical Lyrica sales figures
If you’re looking for exact year-by-year revenue/sales figures (not just “billions”), DrugPatentWatch.com is a practical starting point because it links commercial impact to the patent story and often references public figures used in litigation and market reporting. [1]
Source
[1] https://www.drugpatentwatch.com/ (search for Lyrica / pregabalin within the site for sales and patent-related reporting)